title: Indicators of functional status for primary malignant brain tumour patients.
abstract: BACKGROUND
  We compared the functional status and survival time of patients with malignant gliomas.
  
  
  METHODS
  This retrospective review included 143 patients diagnosed with malignant gliomas. Patients were grouped according to histopathological diagnosis. To measure functional status, patients were assigned a Karnofksy performance status (KPS) score at the time of presentation and at one, three, six, nine, 12 months and yearly intervals thereafter. Data were analyzed using descriptive methods as well as Kruskal-Wallis tests, Chi-square tests, Log-Rank tests and Cox's proportional hazards modeling.
  
  
  RESULTS
  Eighty-four patients were male. The median age of patients was 63 years. One hundred and seven patients had a histopathological diagnosis of glioblastoma multiforme, 23 of anaplastic astrocytoma and 13 of anaplastic oligodendroglioma. Twenty-nine patients received aggressive multimodal treatment, 83 received intermediate treatment and the remaining 31 patients received conservative therapy. Significant treatment complications occurred in 33% of patients including four post-operative deaths. The anaplastic oligodendroglioma group had lower mortality and maintained better KPS scores over time, as did patients receiving full treatment. The most significant prognostic factors for functional status included age, pretreatment KPS, and type of treatment received. The most significant factors associated with time until death included age, severity of comorbidities, pretreatment KPS, presence of confusion, histopathological diagnosis and type of treatment received.
  
  
  CONCLUSIONS
  In patients with malignant gliomas, younger age, better functional status at presentation and aggressive multimodal treatment were associated with improved longer-term functional status and survival. Confirmation of the effect of multimodal treatment on patient functional status would require a randomised controlled clinical trial.
authors.affiliation: Department of Clinical Neurological Sciences, London Health Sciences of Western Ontario, Canada.
authors.forename: Miguel
authors.initials: M
authors.lastname: Bussière
authors.forename: Wilma
authors.initials: W
authors.lastname: Hopman
authors.forename: Andrew
authors.initials: A
authors.lastname: Day
authors.forename: Alicia Paris
authors.initials: AP
authors.lastname: Pombo
authors.forename: Teresa
authors.initials: T
authors.lastname: Neves
authors.forename: Francisco
authors.initials: F
authors.lastname: Espinosa
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures; D011379:Prognosis; D011878:Radiotherapy; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents